Market News & Trends
Lumosa Therapeutics Announces Positive Results From LT3001 Phase 2a Clinical Trial in Acute Ischemic Stroke
Lumosa Therapeutics recently announced its Phase 2a clinical trial of LT3001 successfully met its primary safety endpoint. Further, efficacy showed potential for improvements in neurological…
Pace Life Sciences Acquires Drug Delivery Experts, Expanding Capacity & Injectable Drug Product Services
Pace Analytical Life Sciences, LLC, a subsidiary of Pace Analytical Services, LLC, a full-service contract development and manufacturing organization (CDMO), recently announced it has acquired Drug Delivery Experts, LLC (DDE)…..
CatSci & Argonaute RNA Partner to Expedite Oligonucleotide Manufacturing for Gene-Silencing Therapeutics
CatSci Ltd and Argonaute RNA recently announced a chemistry, manufacturing, and control (CMC) development collaboration focused on novel therapeutic oligonucleotides…..
Lantern Pharma & Allarity Therapeutics Enter Into Agreement for Future Clinical Development of Irofulven
Allarity Therapeutics A/S and Lantern Pharma Inc. recently announced they have entered into an exclusive agreement under which Lantern will reacquire global rights to Irofulven (LP-100) and assume full….
Organon & ObsEva Enter Global Development & Commercialization License Agreement
Organon and ObsEva recently announced they have entered into an agreement whereby Organon will license the global development, manufacturing, and commercial rights to ebopiprant….
Abzena & BioXpress Therapeutics Announce Development & Manufacturing Partnership
Abzena and BioXpress Therapeutics recently announced their partnership to support biosimilar development for third-party customers. The partnership creates an….
Entasis Therapeutics & Zai Lab Complete Patient Enrollment in the ATTACK Phase 3 Registrational Clinical Trial
Entasis Therapeutics Holdings Inc. and Zai Lab Limited recently announced that patient enrollment in the ATTACK Phase 3 registrational clinical trial of sulbactam-durlobactam (SUL-DUR) is…
AC Immune Acquires AFFiRiS’ Specific Active Immunotherapy (SAIT) Anti-Alpha-Synuclein Programs Targeting Neurodegenerative Diseases
AFFiRiS AG recently announced that AC Immune SA is acquiring AFFiRiS’ anti-alpha-synuclein programs targeting neurodegenerative diseases caused by misfolded forms of human self-proteins. All acquired…
Dyadic Announces Technology Transfer & Licensing Agreement With South Africa’s Rubic Consortium
Dyadic International, Inc. recently announced it signed a COVID-19 vaccine technology transfer and licensing agreement with the Rubic Consortium, a South African-based company whose mission…
ValenzaBio Partners With ProBioGen to Maximize Cell Line Productivity & Licenses GlymaxX
ProBioGen and ValenzaBio recently announced the initiation of a cell line development project involving the application of ProBioGen's proprietary GlymaxX technology. ValenzaBio's VB119 is a…
LEXEO Therapeutics Receives Rare Pediatric Disease Designation & Orphan Drug Designation
LEXEO Therapeutics recently announced that the US FDA has granted Rare Pediatric Disease designation and Orphan Drug designation to LX1004 for the treatment of CLN2…
Catalent Launches New OptiDose Design Solution to Help Create Differentiated Treatments That Are Successful for Innovators, Patients & Health Care Professionals
Catalent recently announced the launch of its new OptiDose Design Solution, at the Controlled Release Society (CRS) annual meeting, which is took place virtually from July…
AMRI Becomes Curia
Albany Molecular Research, Inc. (AMRI), a leading global contract research, development and manufacturing organization serving the pharmaceutical and biopharmaceutical industries, today announced that it is…
Catalent Plans Multi-Phase, $100 Million Expansion of Italian Facility to Increase Biologics Manufacturing Capabilities in Europe
SOMERSET, N.J. – July 21, 2021 — Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and…
Strathclyde University conclude that membrane technology could revolutionize vaccine and therapeutics production
Whilst paying tribute to to the hugely impressive efforts of those who reconfigured existing equipment at speed into a "Generation 1" manufacturing process for mRNA…
Catalent Signs Agreement with JOS Pharmaceuticals to Develop Fast-Dissolve ZydisR Formulation for Cannabidiol as an Anesthesia Premedication
Catalent Signs Agreement with JOS Pharmaceuticals to Develop Fast-Dissolve ZydisR Formulation for Cannabidiol as an Anesthesia Premedication Catalent, the leading global provider of advanced delivery…
Curia, the former AMRI, to Acquire Integrity Bio, Expanding Its Biologic Formulation and Fill-Finish Capabilities
One day after announcing its name change to Curia, leading contract research, development and manufacturing organization AMRI reported it has entered into a definitive agreement…
SPI Pharma launches UltraBurst™, the first in class preformulated platform for flash orally dispersible tablets.
SPI Pharma introduces UltraBurst™, providing a step-change in the most critical orally disintegrating tablet (ODT) characteristics — dissolution time. It is an innovative excipient platform…
Collaboration Between AbbVie, Biogen & Pfizer Creates World’s Largest Browsable Resource Linking Rare Protein-Coding Genetic Variants to Human Health & Disease
Today, access to the world’s largest browsable resource linking rare protein-coding genetic variants to human health and disease was launched through a genetic exome sequence…
Cyclerion Therapeutics & Beacon Biosignals Announce Expanded Strategic Partnership
Cyclerion Therapeutics, Inc. and Beacon Biosignals recently announced an extended and expanded strategic partnership between the two companies. This collaboration is expected to identify disease-relevant…
